Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

BACKGROUND: The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 ral...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jonathan Z., Chapman, Brad, Charlebois, Patrick, Hofmann, Oliver, Weiner, Brian, Porter, Alyssa J., Samuel, Reshmi, Vardhanabhuti, Saran, Zheng, Lu, Eron, Joseph, Taiwo, Babafemi, Zody, Michael C., Henn, Matthew R., Kuritzkes, Daniel R., Hide, Winston, Wilson, Cara C., Berzins, Baiba I., Acosta, Edward P., Bastow, Barbara, Kim, Peter S., Read, Sarah W., Janik, Jennifer, Meres, Debra S., Lederman, Michael M., Mong-Kryspin, Lori, Shaw, Karl E., Zimmerman, Louis G., Leavitt, Randi, De La Rosa, Guy, Jennings, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946168/
https://www.ncbi.nlm.nih.gov/pubmed/24603872
http://dx.doi.org/10.1371/journal.pone.0090485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946168/
https://www.ncbi.nlm.nih.gov/pubmed/24603872
http://dx.doi.org/10.1371/journal.pone.0090485

Ejemplares similares